PharmaFocus Today – Page 123 – media

Liu Yongjun returns to Huapu Biotechnology as Chairman

On January 16, 2025, Huapu Biotechnology completed the company’s change registration, the board of directors was adjusted, and Liu Yongjun was appointed as the chairman. This is also the first time that Liu Yongjun has clearly announced his new destination since leaving Shiyao Group in December last year. Huapu Biotechnology was founded in 2001 and is located in Shijiazhuang, Hebei Province. Based on immunology, it focuses on the development of new drugs in the fields of tumors, infections, and autoimmune diseases. At present, a CpG technology platform has been established for the development of innovative vaccines, tumor immunotherapy, etc. Liu Yongjun was established as a scientific founder at the beginning of the company, and another scientific founder was Professor Chen Jianzhu. Wang Xinzhong, the founder of Fushengkang, served as the global R&D president and chief scientist of the company after the merger was completed. The three R&D experts are all ...
- Source: drugdu
- 273
- February 1, 2025
Trump signs executive order, US to withdraw from WHO

Soon after taking office for his second term, US President Donald Trump signed an executive order on Monday (January 20) directing the United States to withdraw from the World Health Organization (WHO), saying the agency had mishandled the Covid-19 pandemic and other international health crises. Trump said the WHO failed to act independently of “undue political influence from WHO member states” and also asked the United States to “unfairly pay huge fees” that were disproportionate to the amounts provided by other larger countries such as China. “The World Health Organization ripped us off, and everyone ripped off the United States. That won’t happen again,” Trump said as he signed an executive order to withdraw from the organization at the White House just hours after taking office. The WHO did not immediately respond to a request for comment. The move means the United States will withdraw from the UN health agency ...
- Source: drugdu
- 260
- February 1, 2025
Sinocell turns losses into profits

In the tide of the capital market, the performance of enterprises is like a beacon, guiding the direction of investors. The 2024 annual performance profit forecast announcement of Sinocell undoubtedly brought a touch of light to many followers. Recently, Sinocell officially released the 2024 annual performance profit forecast announcement. As a leading company in China’s biopharmaceutical industry, Sinocell has achieved significant performance growth in the past year: the company expects to achieve revenue of 2.48 billion yuan to 2.54 billion yuan during the reporting period, a year-on-year increase of more than 30%; net profit attributable to the owners of the parent company is expected to be 0.9 billion yuan to 1.3 billion yuan; net profit attributable to the owners of listed companies after deducting non-recurring gains and losses is expected to be 450 million yuan to 490 million yuan. So far, all three major performance indicators of Sinocell are expected ...
- Source: drugdu
- 198
- February 1, 2025
The mystery behind WuXi AppTec’s “selling, selling, selling”

With the expected failure of the US Biosafety Act, just like Godot who will never show up, industry and capital participants have to think about the real role and value provided by CXO in the industry during the long wait. This experience is not only a test of patience, but also prompts everyone to think deeply. Just as people were speculating on the direction of the bill under the new government and the new Congress, WuXi AppTec (54.570, -0.92, -1.66%) unexpectedly began to sell assets frequently. First, on December 24 last year, it announced the sale of two cell gene therapy companies in the United States and the United Kingdom; then it sold part of its shares in WuXi Helian for more than 2 billion yuan; on January 18 this year, WuXi AppTec announced again that it would sell its US medical device testing platform to the US medical device ...
- Source: drugdu
- 242
- February 1, 2025
The trend of innovative stem cell drugs has arrived!

Stem cells have strong self-repair and regeneration capabilities. Stem cell regeneration intervention has always been considered to be able to cure a variety of difficult and complicated diseases. In recent years, the pace at which global pharmaceutical companies have made breakthroughs in the field of stem cell therapy has continued to accelerate. Data show that by the end of 2024, there will be more than 8,300 related projects on the US Clinical Trials Registry website. Other data predict that by 2034, the global stem cell market size will grow to approximately US$48.83 billion, an increase of more than 200% from US$15 billion in 2023. It is reported that recently, in the field of stem cells, good news has been repeatedly reported in domestic and foreign markets. For example, on December 18, 2024, the US FDA announced the approval of Mesoblast’s allogeneic bone marrow mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel) ...
- Source: drugdu
- 262
- February 1, 2025
Altman’s biotech company is raising $1 billion to extend human life by 10 years

San Francisco biotech company Retro Biosciences is raising $1 billion to support its mission to extend human life by 10 years through artificial intelligence (AI) technology. The company plans to advance its first drug to clinical trials this year. Retro Biosciences’ seed funding was provided by OpenAI CEO Sam Altman, with an amount of $180 million, and Altman will also invest additional funds in this round of Series A financing. The company is currently in talks with family offices, venture capital institutions, sovereign wealth funds, and a US “hyperscale” data center, which will provide it with the computing power needed to run AI models to accelerate drug development and testing. Retro Biosciences has developed a custom AI model in collaboration with OpenAI that can design proteins to temporarily convert ordinary cells into stem cells, thereby reversing the cellular aging process. The company plans to use the financing to fund clinical ...
- Source: drugdu
- 536
- February 1, 2025
The results of the selection of over 70 types of consumables for centralized procurement are about to be implemented

In 2024, the improvement of quality and expansion of consumables through centralized procurement will accelerate, and multiple high-value consumables will achieve significant price reductions; At the same time, the coverage of centralized procurement of in vitro diagnostic reagents is expanding, and the IVD industry is undergoing a comprehensive transformation. According to the statistics of Yaozhi Medical Equipment, about 10 large-scale consumables procurement projects were carried out in 2024, involving various types of consumables such as cochlear implants, peripheral interventions, IVD reagents, etc., and many varieties have not experienced centralized procurement and price reduction before. High value consumables, centralized procurement acceleration In 2024, the storm of centralized procurement in the high-value consumables field has not stopped, and multiple consumables have achieved significant price reductions. Among them, the results of centralized procurement of consumables in the intervention field are particularly significant. In the fifth batch of high-value consumables for national procurement, the ...
- Source: drugdu
- 248
- January 31, 2025
Two innovative medical devices have been approved for market launch

On January 20th, the National Medical Products Administration approved the registration applications for Xinuopu Medical Technology (Beijing) Co., Ltd.’s “Cryoablation Device” and Wuhan Kaidewis Biotechnology Co., Ltd.’s “Human CDO1/AJAP1/GALR1 Gene Methylation Detection Kit (Fluorescent PCR Method)”, two innovative products. Xinnopu Medical specializes in the field of electrophysiology Xinnopu Medical, founded in 2005, has been focusing on the field of cardiac electrophysiology for nearly 20 years and continues to lead industry technological innovation. It is a leader in the Chinese atrial septal puncture market. At present, Xinnopu Medical’s existing products cover dozens of categories including atrial septal puncture instruments, diagnostic instruments, and therapeutic instruments, and have established a complete business system covering research and development, manufacturing, and sales. Xinnopu Medical is actively promoting revolutionary innovation projects such as cryoablation system (Nordica), 3D mapping system (Meridian), intracardiac ultrasound (ICE) diagnostic catheter and equipment (enVision) with the innovation research and development center in ...
- Source: drugdu
- 198
- January 31, 2025
Si Longlong’s team develops a new strategy for attenuated live vaccines based on PROTAC

Influenza is a common respiratory infectious disease that spreads rapidly and is prone to mutation. According to statistics from the World Health Organization (WHO), there are approximately 1 billion cases of seasonal influenza worldwide each year. Vaccination is one of the most economical and effective means of preventing and controlling influenza. On January 15, 2025, Si Longlong’s team from the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, published two important research results in the two top international journals Nature Microbiology and Nature Chemical Biology at the same time, providing a new idea for the development of influenza vaccines. Breakthrough 1: Constructing a PROTAR influenza vaccine library to expand vaccine diversity Traditional vaccines have poor immune effects and safety risks when facing frequent virus mutations, and the development cycle is long and complicated. In 2022, Si Longlong’s team pioneered the PROTAR attenuated live vaccine technology, ...
- Source: drugdu
- 280
- January 31, 2025
Baili Tianheng’s revenue is expected to increase by 932%

On January 21, Baili Tianheng released its 2024 performance forecast, expecting to achieve annual operating income of approximately 5.8 billion yuan, a year-on-year increase of 932.27%; the net profit attributable to the parent company’s owners is expected to be 3.6 billion yuan, an increase of 4.38 billion yuan from the same period last year, and will turn losses into profits. The notice disclosed that this significant performance growth was mainly due to the irrevocable, non-deductible down payment of US$800 million paid by the company’s overseas partner Bristol-Myers Squibb (BMS) for its core product BL-B01D1 during the reporting period, which led to a significant increase in the company’s operating income. BL-B01D1 is a dual-antibody ADC targeting EGFR×HER3. It is the world’s first and only drug of its kind to enter the clinical stage. At the end of 2023, SystImmune, a wholly-owned subsidiary of Baili Tianheng, reached an exclusive licensing and cooperation ...
- Source: drugdu
- 277
- January 30, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.